Episurf Medical

EPIC-Knee: Episealer Knee System IDE Clinical Study is a prospective, randomised, controlled, multi-centre study to evaluate the safety and effectiveness of the Episealer Knee System compared to microfracture for the treatment of focal femoral knee chondral or osteochondral lesions.

For patients with isolated osteoarthritis of the patellofemoral joint, the Episealer Patellofemoral System consists of personalized implants on both femur and patella, preserving as much bone as possible by treating only the damaged areas of the joint.

*de Caro, F., et al., Satisfactory survivorship and clinical outcomes up to 10 years after the implantation of a novel personalized metal implant for the treatment of osteochondral lesions of the knee. J ISAKOS, online October 2025. (full publication)

The page describes osteoarthritis as joint inflammation caused by trauma, repeated micro-traumas, or wear-and-tear, leading to cartilage breakdown and bone rubbing.

A joint is the point at which two or more bones come together.

Episurf Medical AB’s 2019 annual report is available online; printed copies are distributed only upon request.

Dr. Schramm introduced Episealer after learning about it at the German orthopaedic convention in Berlin in 2015, drawn to its innovative approach and prior biomechanical research at FAU-Erlangen University.

The page lists alternative cartilage lesion treatments, depending on severity, progression, and patient factors like age and lifestyle.

In orthopaedic innovation terms, compared to both younger and older patient cohorts, middle-aged patients have been left behind over the last generation.

Episurf Medical AB is a publicly listed Swedish company based in Stockholm, with shares traded on Nasdaq Stockholm since June 11, 2014. Its governance follows Swedish laws, regulations, and instructions, dividing roles among shareholders, the board, CEO, and executive management.

Episurf’s whistleblowing directive allows employees, customers, partners, and other stakeholders to anonymously report suspected violations of laws and regulations via Huma HR.

2626 Cole Avenue Suite 300 Dallas, TX 75204 United States

Pioneer in personalized technology for treating painful joint injuries. Custom orthopedic implants & surgical instruments for each patient.

Oligo Medic Inc. has signed a letter of intent to acquire Episurf Medical AB’s imaging-based custom implant business. Episurf specializes in patient-specific implants and surgical tools for joint preservation procedures. The deal targets expanding Oligo Medic’s portfolio in orthopedic solutions.

Oct 2026BioSpaceNews article

Episurf Medical has signed a letter of intent with Oligo Medic for the potential sale of its medical technology business. The agreement follows Episurf’s strategic review, announced in October 2026, as the company shifts focus toward property operations. The deal remains subject to further negotiations and finalization.

Oct 2026News Powered by CisionNews article

Episurf Medical acquires eight properties in Hudiksvall for SEK 300 million, excluding one previously listed asset. The portfolio spans 16,300 m² of leasable space, complementing the company’s existing real estate holdings in the region. The deal finalizes the purchase of properties previously outlined in a December 2025 announcement.

Oct 2026News Powered by CisionNews article

Episurf Medical AB is transitioning into a **pure-play property company**, focusing resources on its **Nordic property operations**. The board has decided to **initiate an orderly wind-down of its medtech business** as part of a dual-track strategic review. The company evaluates potential **sale or spin-off options** for its medical technology segment.

Aug 2026Episurf MedicalNews article